Heterocyclic organobismuth(III) compound targets tubulin to induce G2/M arrest in HeLa cells.
Our previous study showed that organobismuth compounds induce apoptosis in human promyelocytic leukemia cells, although solid tumor cell lines were relatively resistant. Herein, we investigated the primary cellular target of these compounds in HeLa cells. One organobismuth compound, bi-chlorodibenzo[c,f][1,5]thiabismocine (compound 3), arrested the cell cycle at G(2)/M as assessed by flow cytometry and by upregulating the expression of cyclin B1. At a low concentration (0.5 microM), compound 3 caused cell cycle arrest at the mitotic phase and induced apoptosis. At a higher concentration (>1.0 microM), it induced an arrest in the G(2)/M phase, leading to apoptosis. In many cells blocked at the M phase, the organization of microtubules was affected, indicating depolymerization of the microtubule network. Western blotting demonstrated that compound 3 depolymerized microtubules similar to colchicine and nocodazole. Experiments in vitro also showed that compound 3 inhibited the assembly of purified tubulin in a concentration-dependent manner by interacting with the colchicine-binding site of tubulin through its SH groups. Heterocyclic organobismuth compounds are novel tubulin ligands.
Department of Bioscience, Faculty of Science and Technology, Kwansei Gakuin University, Sanda, Japan.
Katsuya
K
Iuchi
Kiwamu
K
Akagi
Tatsuo
T
Yagura
D017304:Annexin A5 / Q000378:metabolism; D001729:Bismuth / Q000494:pharmacology*; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects*; D016923:Cell Death / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D003078:Colchicine / Q000494:pharmacology; D004396:Coloring Agents; D005434:Flow Cytometry; D016195:G2 Phase / Q000187:drug effects*; D006367:HeLa Cells; D006571:Heterocyclic Compounds / Q000494:pharmacology*; D006801:Humans; D007150:Immunohistochemistry; D008870:Microtubules / Q000187:drug effects; D008940:Mitotic Index; D011419:Propidium; D013438:Sulfhydryl Compounds / Q000494:pharmacology; D014404:Tubulin / Q000187:drug effects* / Q000378:metabolism; D014410:Tumor Stem Cell Assay
D017304:Annexin A5; D004396:Coloring Agents; D006571:Heterocyclic Compounds; D013438:Sulfhydryl Compounds; D014404:Tubulin; D011419:Propidium; D003078:Colchicine; D001729:Bismuth